VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study
In poor-responsive nAMD, switching to BRZ or FAR under a TAE regimen without upload achieved stable vision, sustained CST reduction, and comparable treatment burden over one year. FAR showed greater fvPED regression and a slight functional trend, while BRZ achieved faster fluid resolution with fewer injections.
Authors
- Armin Wolf
- Efstathios Vounotrypidis (ORCID: https://orcid.org/0000-0002-9833-2200)
- Adnan Kilani
- Vasiliki Moysidi
- Abdelrahman Assaf
- Denise Vogt
Institutions
- University Hospital Ulm (DE)
Publication Details
- Journal
- Graefe s Archive for Clinical and Experimental Ophthalmology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1007/s00417-025-07091-2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00